Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...
SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...
Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...
SAN FRANCISCO -- The pediatric Crohn's disease exclusion diet was associated with clinical remission for children with good ...
Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback